Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Progressive Corp (PGR) Price & Performance

Mesoblast LimitedTrade
Progressive CorpTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Progressive Corp — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Progressive Corp trades at $212.5 (market cap $124.38B). The key difference: Progressive Corp is far larger — about 57.6× Mesoblast Limited's market cap, and Progressive Corp pays a 6.5% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESOPGR
Market Cap
$2.16B$124.38B
Sector
TechnologyFinancials
52-Week High
$20.96$252.68
52-Week Low
$12.88$190.40
Enterprise Value
$2.17B$132.59B
Dividend Yield
6.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Progressive Corp

Progressive (PGR) trades at $215.33, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates robust revenue growth, rising from $49.6B in 2022 to $87.6B in 2025, with net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 EPS, though Q1 2026 slightly missed. The current P/E ratio of 10.8 suggests reasonable valuation relative to earnings strength.

The outlook for PGR remains positive with a consensus price target of $231.20, indicating potential upside. Key opportunities include expanding bundled insurance offerings and solid profitability metrics like 34.94% ROE. Risks involve competitive pressures in auto insurance and potential margin compression from growth investments. Analyst sentiment is mixed with 36.59% buy ratings, reflecting cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR